{"id":"asp4070","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ASP4070 blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. By inhibiting this key inflammatory pathway, the drug aims to reduce tissue damage and inflammation in complement-driven diseases.","oneSentence":"ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:21:23.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complement-mediated inflammatory diseases (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT03101267","phase":"PHASE2","title":"A Dose-finding Study of ASP4070","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-04-13","conditions":"Rhinitis, Allergic, Seasonal","enrollment":150},{"nctId":"NCT02469688","phase":"PHASE1","title":"A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-06-18","conditions":"Cedar Pollinosis","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASP4070","genericName":"ASP4070","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Complement-mediated inflammatory diseases (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}